Literature DB >> 24257755

Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation.

Ananya Roy1, Goutham Ganesh, Helena Sippola, Sara Bolin, Osama Sawesi, Anders Dagälv, Susan M Schlenner, Thorsten Feyerabend, Hans-Reimer Rodewald, Lena Kjellén, Lars Hellman, Magnus Åbrink.   

Abstract

During infection and tissue damage, virulence factors and alarmins are pro-inflammatory and induce activation of various immune cells including macrophages and mast cells (MCs). Activated MCs instantly release preformed inflammatory mediators, including several proteases. The chymase mouse mast cell protease (MCPT)-4 is thought to be pro-inflammatory, whereas human chymase also degrades pro-inflammatory cytokines, suggesting that chymase instead limits inflammation. Here we explored the contribution of MCPT4 and human chymase to the control of danger-induced inflammation. We found that protein extracts from wild type (WT), carboxypeptidase A3-, and MCPT6-deficient mice and MCs and recombinant human chymase efficiently degrade the Trichinella spiralis virulence factor heat shock protein 70 (Hsp70) as well as endogenous Hsp70. MC-(W(sash))-, serglycin-, NDST2-, and MCPT4-deficient extracts lacked this capacity, indicating that chymase is responsible for the degradation. Chymase, but not MC tryptase, also degraded other alarmins, i.e. biglycan, HMGB1, and IL-33, a degradation that was efficiently blocked by the chymase inhibitor chymostatin. IL-7, IL-22, GM-CSF, and CCL2 were resistant to chymase degradation. MCPT4-deficient conditions ex vivo and in vivo showed no reduction in added Hsp70 and only minor reduction of IL-33. Peritoneal challenge with Hsp70 resulted in increased neutrophil recruitment and TNF-α levels in the MCPT4-deficient mice, whereas IL-6 and CCL2 levels were similar to the levels found in WT mice. The rapid and MC chymase-specific degradation of virulence factors and alarmins may depend on the presence of accessible extended recognition cleavage sites in target substrates and suggests a protective and regulatory role of MC chymase during danger-induced inflammation.

Entities:  

Keywords:  Biglycan; High Mobility Group Box Protein 1; Hsp70; IL-33; Inflammation; Innate Immunity; Mast Cell; Serine Protease; Tumor Necrosis Factor (TNF); Virulence Factors

Mesh:

Substances:

Year:  2013        PMID: 24257755      PMCID: PMC3879547          DOI: 10.1074/jbc.M112.435156

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

1.  Cytokine production by skin-derived mast cells: endogenous proteases are responsible for degradation of cytokines.

Authors:  Wei Zhao; Carole A Oskeritzian; Andrea L Pozez; Lawrence B Schwartz
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

2.  Mast cells can enhance resistance to snake and honeybee venoms.

Authors:  Martin Metz; Adrian M Piliponsky; Ching-Cheng Chen; Verena Lammel; Magnus Abrink; Gunnar Pejler; Mindy Tsai; Stephen J Galli
Journal:  Science       Date:  2006-07-28       Impact factor: 47.728

Review 3.  Alarmin(g) news about danger: workshop on innate danger signals and HMGB1.

Authors:  Helena Erlandsson Harris; Angela Raucci
Journal:  EMBO Rep       Date:  2006-07-21       Impact factor: 8.807

4.  Extracellular HSP70 binding to surface receptors present on antigen presenting cells and endothelial/epithelial cells.

Authors:  Jimmy R Thériault; Salamatu S Mambula; Tatsuya Sawamura; Mary Ann Stevenson; Stuart K Calderwood
Journal:  FEBS Lett       Date:  2005-03-28       Impact factor: 4.124

5.  A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2.

Authors:  Elena Tchougounova; Anders Lundequist; Ignacio Fajardo; Jan-Olof Winberg; Magnus Abrink; Gunnar Pejler
Journal:  J Biol Chem       Date:  2004-12-22       Impact factor: 5.157

6.  HMGB1 signals through toll-like receptor (TLR) 4 and TLR2.

Authors:  Man Yu; Haichao Wang; Aihao Ding; Douglas T Golenbock; Eicke Latz; Christopher J Czura; Matthew J Fenton; Kevin J Tracey; Huan Yang
Journal:  Shock       Date:  2006-08       Impact factor: 3.454

7.  High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin.

Authors:  De Yang; Qian Chen; Huan Yang; Kevin J Tracey; Michael Bustin; Joost J Oppenheim
Journal:  J Leukoc Biol       Date:  2006-09-11       Impact factor: 4.962

8.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages.

Authors:  Liliana Schaefer; Andrea Babelova; Eva Kiss; Heinz-J Hausser; Martina Baliova; Miroslava Krzyzankova; Gunther Marsche; Marian F Young; Daniel Mihalik; Martin Götte; Ernst Malle; Roland M Schaefer; Hermann-Josef Gröne
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

9.  Loss of histochemical identity in mast cells lacking carboxypeptidase A.

Authors:  Thorsten B Feyerabend; Heinz Hausser; Annette Tietz; Carmen Blum; Lars Hellman; Anita H Straus; Hélio K Takahashi; Ellen S Morgan; Ann M Dvorak; Hans Jörg Fehling; Hans-Reimer Rodewald
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

10.  Mast cell-dependent activation of pro matrix metalloprotease 2: A role for serglycin proteoglycan-dependent mast cell proteases.

Authors:  Anders Lundequist; Magnus Abrink; Gunnar Pejler
Journal:  Biol Chem       Date:  2006 Oct-Nov       Impact factor: 3.915

View more
  49 in total

1.  TGF-β1 Suppresses IL-33-Induced Mast Cell Function.

Authors:  Victor S Ndaw; Daniel Abebayehu; Andrew J Spence; Patrick A Paez; E Motunrayo Kolawole; Marcela T Taruselli; Heather L Caslin; Alena P Chumanevich; Anuya Paranjape; Bianca Baker; Brian O Barnstein; Tamara T Haque; Kasalina N Kiwanuka; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

2.  IL-33/ST2 axis promotes mast cell survival via BCLXL.

Authors:  Jun-Xia Wang; Shinjiro Kaieda; Sarah Ameri; Nadia Fishgal; Daniel Dwyer; Anthony Dellinger; Christopher L Kepley; Michael F Gurish; Peter A Nigrovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-30       Impact factor: 11.205

Review 3.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

4.  Granulocytes in Ocular HSV-1 Infection: Opposing Roles of Mast Cells and Neutrophils.

Authors:  Derek J Royer; Min Zheng; Christopher D Conrady; Daniel J J Carr
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-06       Impact factor: 4.799

Review 5.  Mast cell secretory granules: armed for battle.

Authors:  Sara Wernersson; Gunnar Pejler
Journal:  Nat Rev Immunol       Date:  2014-06-06       Impact factor: 53.106

6.  Central domain of IL-33 is cleaved by mast cell proteases for potent activation of group-2 innate lymphoid cells.

Authors:  Emma Lefrançais; Anais Duval; Emilie Mirey; Stéphane Roga; Eric Espinosa; Corinne Cayrol; Jean-Philippe Girard
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-13       Impact factor: 11.205

7.  Proteome analysis of mast cell releasates reveals a role for chymase in the regulation of coagulation factor XIIIA levels via proteolytic degradation.

Authors:  Nicholas J Shubin; Veronika A Glukhova; Morgan Clauson; Phuong Truong; Magnus Abrink; Gunnar Pejler; Nathan J White; Gail H Deutsch; Stephen R Reeves; Tomas Vaisar; Richard G James; Adrian M Piliponsky
Journal:  J Allergy Clin Immunol       Date:  2016-05-13       Impact factor: 10.793

Review 8.  Mast cells as sources of cytokines, chemokines, and growth factors.

Authors:  Kaori Mukai; Mindy Tsai; Hirohisa Saito; Stephen J Galli
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

Review 9.  Novel Insight into the in vivo Function of Mast Cell Chymase: Lessons from Knockouts and Inhibitors.

Authors:  Gunnar Pejler
Journal:  J Innate Immun       Date:  2020-06-04       Impact factor: 7.349

10.  Mouse mast cell proteases 4 and 5 mediate epidermal injury through disruption of tight junctions.

Authors:  Lora G Bankova; Cecilia Lezcano; Gunnar Pejler; Richard L Stevens; George F Murphy; K Frank Austen; Michael F Gurish
Journal:  J Immunol       Date:  2014-02-12       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.